Corrigendum to "Novel benzimidazole derivatives as selective CB2 agonists" [Bioorg. Med. Chem. Lett. 18 (2008) 3695-3700] (DOI:10.1016/j.bmcl.2008.05.073);Novel benzimidazole derivatives as selective CB2 agonists

Bioorganic and Medicinal Chemistry Letters

Volumn 18, Issue 13, 2008, Pages 3695-3700

  Pagé, Daniel ^a   Balaux, Elise ^a   Boisvert, Luc ^a   Liu, Ziping ^a   Milburn, Claire ^a   Tremblay, Maxime ^a   Wei, Zhongyong ^a   Woo, Simon ^a   Luo, Xuehong ^a   Cheng, Yun Xing ^a   Yang, Hua ^a   Srivastava, Sanjay ^a   Zhou, Fei ^a   Brown, William ^a   Tomaszewski, Miroslaw ^a   Walpole, Christopher ^a   Hodzic, Leila ^a   St Onge, Stéphane ^a   Godbout, Claude ^a   Salois, Dominic ^a   Payza, Keymal ^a   more..

^a ASTRAZENECA   (United Kingdom)

Author keywords

Agonists; Benzimidazoles; Cannabinoids; CB2 receptor

Indexed keywords

1,2,3,4 TETRAHYROPYRROLOINDOLE AGONIST; AMIDE; AMINE; AMMONIUM HYDROXIDE; ANILINE DERIVATIVE; BENZIMIDAZOLE DERIVATIVE; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID RECEPTOR AGONIST; KETONE; PHENYLACETIC ACID DERIVATIVE; WATER;

ARTICLE; BINDING AFFINITY; CATALYSIS; CYCLIZATION; DRUG STRUCTURE; DRUG SYNTHESIS; HYDROGENATION; PROTEIN BINDING; PROTEIN FOLDING; PROTEIN MODIFICATION; REVERSED PHASE LIQUID CHROMATOGRAPHY;

EID: 44849117524     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2008.07.104     Document Type: Erratum

References (49)

1. Cervino C., Pasquali R., and Pagotto U. Mini-Rev. Med. Chem. 7 (2007) 21
2. Tucci S.A., Halford J.C.G., Harrold J.A., and Kirkham T.C. Curr. Med. Chem. 13 (2006) 2669
3. Hohmann A.G., and Suplita R.L. AAPS J. 8 (2006) E693
4. Goya P., Jagerovic N., Hernandez-Folgado L., and Martin M.I. Mini-Rev. Med. Chem. 3 (2003) 765
5. Richardson J.D. J. Pain 1 (2000) 2
6. Lopez-Rodriguez M., Viso A., Ortega-Gutiérrez S., and Diaz-Laviada I. Mini-Rev. Med. Chem. 5 (2005) 97
7. Drysdale A.J., and Platt B. Curr. Med. Chem. 10 (2003) 2719
8. Pertwee R.G. Br. J. Pharmacol. 147 (2006) S163
9. Jonsson K.O., Holt S., and Fowler C. Basic Clin. Pharmacol. Toxicol. 98 (2006) 124
10. Mackie K. Annu. Rev. Pharmacol. Toxicol. 46 (2006) 101
11. Pacher P., Batkai S., and Kunos G. Pharmacol. Rev. 58 (2006) 389
12. Howlett A.C., Breivogel C.S., Childers S.R., Deadwyler S.A., Hampson R.E., and Porrino L.J. Neuropharmacology 47 (2004) 345
13. Muccioli G.G., and Lambert D.M. Curr. Med. Chem. 12 (2005) 1361
14. Muccioli G.G. Chem. Biodivers. 4 (2007) 1805
15. Das S.K., and Chakrabarti R. Curr. Med. Chem. 13 (2006) 1429
16. Basavarajappa B.S. Mini-Rev. Med. Chem. 7 (2007) 769
17. Ashton J.C., and Milligan E.D. Curr. Opin. Investig. Drugs 9 (2008) 65
18. Russo E., and Guy G.W. Med. Hypotheses 66 (2006) 234
19. Montero C., Campillo N.E., Goya P., and Paez J.A. Eur. J. Med. Chem. 40 (2005) 75
20. Davis M., Maida V., Daeninck P., and Pergolizzi J. Support Care Cancer 15 (2007) 63
21. Whiteside G.T., Lee G.P., and Valenzano K.J. Curr. Med. Chem. 14 (2007) 917
22. Ashton J.C. Curr. Opin. Investig. Drugs 8 (2007) 373
23. Giblin G.M., O'Shaughnessy C.T., Naylor A., Mitchell W.L., Eatherton A.J., Slingsby B.P., Rawlings D.A., Goldsmith P., Brown A.J., Haslam C.P., Clayton N.M., Wilson A.W., Chessell I.P., Wittington A.R., and Green R. J. Med. Chem. 50 (2007) 2597
24. Guindon J., and Hohmann A.G. Br. J. Pharmacol. 153 (2008) 319
25. Khanolkar A.D., Lu D., Ibrahim M., Duclos R.I., Thakur G.A., Malan T.P., Porreca F., Veerappan V., Tian X., George C., Parrish D.A., Papahatjis D.P., and Makriyannis A. J. Med. Chem. 50 (2007) 6493
26. Fernandez-Ruiz J., Romero J., Velasco G., Tolon R.M., Ramos J.A., and Guzman M. Trends Pharmacol. Sci. 28 (2007) 39
27. Maccarrone M., Battista N., and Centonze D. Prog. Neurobiol. 81 (2007) 349
28. Centoze D., Finazzi-Agro A., Bernardi G., and Maccarrone M. Trends Pharmacol. Sci. 28 (2007) 180
29. Micale V., Mazzola C., and Drago F. Pharmacol. Res. 56 (2007) 382
30. McKallip R.J., Lombard C., Fisher M., Martin B.R., Ryu S., Grant S., Nagarkatti P.S., and Nagarkatti M. Blood 100 (2002) 627
31. Velasco G., Galve-Roperh I., Sánchez C., Blázquez C., and Guzmán M. Neuropharmacology 47 (2004) 315
32. Pertwee R.G. Pharmocol. Therapeut. 95 (2002) 165
33. Ofek O., Karsak M., Leclerc N., Fogel M., Frenkel B., Wright K., Tam J., Attar-Namdar M., Kram V., Shohami E., Mechoulam R., Zimmer A., and Bab I. Proc. Natl. Acad. Sci. U.S.A. 103 (2006) 696
34. Idris A.I., van't Hof R.J., Greig I.R., Ridge S.A., Baker D., Ross R.A., and Ralston S.H. Nat. Med. 11 (2005) 774
35. Gertsch J., Raduner S., and Altmann K.H. J. Recept. Signal Transduct. 26 (2006) 709
36. Muccioli G.G., and Lambert D.M. Expert Opin. Ther. Patents 16 (2006) 1405
37. Pavlopoulos S., Thakur G.A., Nikas S.P., and Makriyannis A. Curr. Pharm. Design 12 (2006) 1751
38. Manera C., Cascio M.G., Benetti V., Allara M., Tuccinardi T., Martinelli A., Saccomanni G., Vivoli E., Ghelardini C., Di Marzo V., and Ferrarini P.L. Bioorg. Med. Chem. Lett. 17 (2007) 6505
39. Kai H., Morioka Y., Murashi T., Morita K., Shinonome S., Nakazato H., Kawamoto K., Hanasaki K., Takahashi F., Mihara S., Arai T., Abe K., Okabe H., Baba T., Yoshikawa T., and Takenaka H. Bioorg. Med. Chem. Lett. 17 (2007) 4030
40. Stern E., Muccioli G.G., Millet R., Goossens J.-F., Farce A., Chavatte P., Poupaert J.H., Lambert D., Depreux P., and Hénichart J.-P. J. Med. Chem. 49 (2006) 70
41. Adam J., Cowley P.M., Kiyoi T., Morrison A.J., and Mort C.J.W. Prog. Med. Chem. 44 (2006) 207
42. Verbist B.M.P., De Cleyn M.A.J., Surkyn M., Fraiponts E., Aerssens J., Nijsen M.J.M.A., and Gijsen H.J.M. Bioorg. Med. Chem. Lett. 18 (2008) 2574
43. Pagé D., Yang H., Brown W., Walpole C., Fleurent M., Fyfe M., Gaudreault F., and St-Onge S. Bioorg. Med. Chem. Lett. 17 (2007) 6183
44. Pagé D., Brochu M.-C., Yang H., Brown W., St-Onge S., Martin E., and Salois D. Lett. Drug Des. Discov. 3 (2006) 298
45. Yadav J.S., Reddy G.S., Reddy M.M., and Meshram H.M. Tetrahedron Lett. 39 (1998) 3259
46. 3OD) δ 0.51 (m, 2H), 0.66 (m, 2H), 1.28 (m, 1H), 1.41 (m, 7H), 1.55 (m, 2H), 3.28 (s, 3H), 3.34 (m, 4H), 4.07 (q, 2H), 4.39 (d, 2H), 4.57 (s, 2H), 7.01 (m, 2H), 7.30 (m, 2H), 7.39 (dd, 1H), 7.44 (d, 1H), 7.90 (d, 1H); 447.36 (MH+ monoisot.).
47. H) for ligands in displacing specifically bound radioligand are calculated in Activity base with ExcelFit. The concentration of compounds to use and dilutions are also calculated with Activity base. The radioactivity (cpm) is counted in a TopCount (Packard) after adding 65 μL/well of MS-20 scintillation liquid.
48. 35S] specific binding is calculated by subtracting the BB.
49. Compton D.R., Gold L.H., Ward S.J., Balster R.L., and Martin B.R. J. Pharmacol. Exp. Ther. 263 (1992) 1118